论文部分内容阅读
近年,由于多家上市公司投资阿维菌素、伊维菌素系列,产品,使之倍受瞩目。由于参与竞争的国内各生产厂家相互削价,导致产品价格和盈利能力大幅下降,持续低迷。参与竞争的各企业逐渐分化: 威远生化河北威远1998年7月斥资550万元收购赞皇赞立泰公司并转产生产阿维菌素。1999年开始投资阿维菌素、伊维菌素系列产品项目,其中,12000公斤/年阿维菌素技改项目计划投资4966.3万元,目前已完成投资1260.2万元;4000公斤年伊维菌素技改项目计划投资605.6万元,已完成投资68.2万元;1000公斤/年甲胺基阿维菌素技改项目计划投资864.2万元,已完成投资425万元。计划2000年内实现阿维菌素后续产品的投产,
In recent years, due to a number of listed companies investing in abamectin, ivermectin series, and products, they have attracted attention. As the domestic manufacturers participating in the competition have reduced each other’s prices, the price and profitability of the products have fallen drastically and have continued to slump. Companies participating in the competition gradually differentiate: Weiyuan Biochemical Hebei Weiyuan spent RMB 5.5 million in July 1998 to acquire Zanhuang Zang Litai Company and transfer its production of avermectin. In 1999, the company began to invest in avermectin and ivermectin series products, of which, 12,000 kg/year of avermectin technical transformation project plans to invest 49.963 million yuan, and has completed investment of 126.02 million yuan; 4000 kilograms of ivermectin The technical upgrading project plans to invest 6.056 million yuan, has completed investment of 682,000 yuan; 1000 kg / year of technical innovation projects of methyl avermectin will invest 8.642 million yuan, has completed investment of 4.25 million yuan. It plans to implement the production of avermectin follow-up products in 2000.